Bank of America Corp DE Has $2.17 Million Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Bank of America Corp DE decreased its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 37.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 281,204 shares of the biotechnology company's stock after selling 164,980 shares during the quarter. Bank of America Corp DE owned approximately 0.57% of REGENXBIO worth $2,174,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after acquiring an additional 1,659,206 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in REGENXBIO by 9.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 1,982 shares in the last quarter. BNP Paribas Financial Markets increased its position in REGENXBIO by 370.1% in the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock worth $743,000 after purchasing an additional 75,652 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of REGENXBIO by 34.0% during the 4th quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock worth $374,000 after purchasing an additional 12,285 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of REGENXBIO during the 4th quarter worth about $568,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Insider Activity

In related news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. This trade represents a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.79% of the stock is owned by company insiders.

REGENXBIO Trading Down 18.9%

REGENXBIO stock traded down $1.91 on Thursday, reaching $8.17. 1,825,510 shares of the stock were exchanged, compared to its average volume of 1,067,257. The firm has a fifty day moving average price of $8.01 and a two-hundred day moving average price of $7.95. The stock has a market cap of $409.81 million, a PE ratio of -1.63 and a beta of 1.11. REGENXBIO Inc. has a twelve month low of $5.03 and a twelve month high of $15.36.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. Equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Leerink Partners set a $24.00 price objective on REGENXBIO in a report on Tuesday, March 18th. Chardan Capital reissued a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Wall Street Zen upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Raymond James started coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective for the company. Finally, The Goldman Sachs Group decreased their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.